HomeAI · summaries
Storia in 5 fonti
Metsera accepts Pfizer's $10 billion bid in ongoing M&A battle
Pfizer said it would pay $86.25 per share in cash, a premium of 3.69% to Metsera's Friday close.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
forbes.com
The Multi-Billion-Dollar Battle For Metsera
In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.
- ·
ft.com
Novo Nordisk again raises bid in battle for obesity start-up Metsera
Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs
- ·
cnbc.com
Metsera accepts Pfizer's $10 billion bid in ongoing M&A battle
Pfizer said it would pay $86.25 per share in cash, a premium of 3.69% to Metsera's Friday close.
- ·
ilsole24ore.com
Pfizer vince la guerra con Novo Nordisk e acquisisce Metsera, startup di farmaci dimagranti
Pfizer pagherà fino a 86,25 dollari ad azione, di cui 65,60 dollari ad azione in contanti, più potenziali pagamenti aggiuntivi fino a 20,65 dollari ad azione
- ·
fortune.com
Pfizer beats out Novo Nordisk in bidding for obesity drugmaker Metsera | Fortune
Metsera has no products on the market, but it is developing oral and injectable treatments.
- ·
Novo Nordisk sale a Copenaghen, si ritira da gara miliardaria per Metsera
Accettata l'offerta rivista e migliorata di Pfizer da 10 miliardi di dollari che entra nel mercato dei farmaci contro l'obesità
- ·
Pfizer shows hardball mettle needed to win in 2025 M&A
Pharma giant had to pay a blockbuster price to buy Metsera after the biotech prospect spurred an auction with Novo Nordisk